Technical analysis of Incyte Corporation (INCY): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive a...
Price Performance
| 1 month | +4.41% |
| 3 months | +1.65% |
| Year-to-date | +21.89% |
| 1 year | +28.79% |
| 3 years | +123.07% |
| 5 years | +89.65% |
| 10 years | +44.56% |
52-Week Range
| 52-week High | $132.60 |
| 52-week Low | $89.25 |
| Avg Volume (90d) | 1.7M |
Technical Indicators
| SMA 50 | $120.49 |
| SMA 200 | $108.06 |
| Beta | 0.86 |
| 30-day Volatility (annualised) | 28.3% |
| Price vs SMA 50 | -0.1% |
| Price vs SMA 200 | +11.4% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-12 | $98.77 | |
| 2026-01 | $100.07 | +1.3% |
| 2026-02 | $101.27 | +1.2% |
| 2026-03 | $94.12 | -7.1% |
| 2026-04 | $95.27 | +1.2% |
| 2026-05 | $96.74 | +1.5% |
| 2026-06 | $113.36 | +17.2% |
| 2026-07 | $119.52 | +5.4% |
| 2026-08 | $123.22 | +3.1% |
| 2026-09 | $121.35 | -1.5% |
| 2026-10 | $120.39 | -0.8% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2027-02-09 | $1.89 | $1.54B |
| 2026-10-29 | $-3.93 | $1.46B |
| 2026-07-28 | $2.15 | $1.50B |
| 2026-04-28 | $1.34 | $1.22B |
| 2026-02-10 | $1.90 | $1.35B |
| 2025-10-28 | $1.66 | $1.35B |
| 2025-07-29 | $1.39 | $1.26B |
Price
| Price | $120.39 (closing price, October 30, 2026) |
| Market Cap | $24.5B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 64.04 |
| Price / Book | 4.34 |
| EV / EBITDA | 24.25 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 3.84 |
| Piotroski F-Score | 8 |
| Altman Z-Score | 8.44 |